Agios Pharmaceuticals (NASDAQ:AGIO) received a $83.00 target price from Oppenheimer in a research note issued on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s target price would indicate a potential upside of 45.18% from the stock’s previous close.
Several other research analysts have also recently issued reports on the company. BidaskClub cut Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 16th. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 12th. Cann reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. SunTrust Banks set a $80.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, November 19th. Finally, Credit Suisse Group lifted their price objective on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $75.70.
Shares of Agios Pharmaceuticals (AGIO) traded down $3.45 during trading hours on Tuesday, hitting $57.17. The stock had a trading volume of 317,100 shares, compared to its average volume of 501,806. Agios Pharmaceuticals has a 1 year low of $39.24 and a 1 year high of $72.73. The company has a market capitalization of $2,948.17, a P/E ratio of -9.12 and a beta of 1.83.
In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 80,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $70.14, for a total value of $5,611,200.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 3,838 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $59.37, for a total value of $227,862.06. Following the completion of the sale, the director now directly owns 80,851 shares in the company, valued at approximately $4,800,123.87. The disclosure for this sale can be found here. In the last ninety days, insiders sold 127,746 shares of company stock worth $8,733,196. Corporate insiders own 5.43% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. QS Investors LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $144,000. Cubist Systematic Strategies LLC boosted its holdings in shares of Agios Pharmaceuticals by 1,041.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 3,123 shares during the period. Aperio Group LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $206,000. Teacher Retirement System of Texas purchased a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth approximately $225,000. Finally, S&CO Inc. purchased a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth approximately $227,000. Hedge funds and other institutional investors own 93.79% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Oppenheimer Analysts Give Agios Pharmaceuticals (AGIO) a $83.00 Price Target” was first reported by American Banking and Market News and is the sole property of of American Banking and Market News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/29/oppenheimer-analysts-give-agios-pharmaceuticals-agio-a-83-00-price-target.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
